» Articles » PMID: 1668406

Receptors for Platelet Derived Growth Factor in Human Glioma Cell Lines and Influence of Suramin on Cell Proliferation

Overview
Journal J Neurooncol
Publisher Springer
Date 1991 Dec 1
PMID 1668406
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

A panel of 11 established human glioma cell lines was used to evaluate PDGF receptor binding using radioiodinated biosynthetic PDGF-AA and PDGF-AB as primary ligands. It was found that PDGF-receptor-binding was qualitatively heterogeneous. The affinities for PDGF-AA as well as PDGF-AB binding were within a close range of 0.13-0.33 nM and 0.16-1.1 nM, respectively. The number of binding sites per cell ranged between 56.000 and 250.000 for PDGF-AA and 72.000 to 300.000 for PDGF-AB. Two lines had only background levels of PDGF-AA binding. PDGF-AB binding was the dominant binding component in all but one cell line. In seven cell lines there were two binding components upon saturation analysis consisting of a high affinity component and a non-saturable low affinity component. PDGF and PDGF-receptors are suspected to be part of an autocrine loop in gliomas. Therefore, the effect of suramin on cell proliferation in serumfree cultures was tested in the same cell lines using doses of 25,200 or 500 micrograms/ml. It was found that the response to suramin was variable and that two cell lines still reached 2.8 fold and 4.5 fold their initial cell density even in the presence of 500 micrograms/ml whereas all other cells were completely arrested. Analyzing the response to 200 micrograms/ml it became evident, that the PDGF binding characteristics are of no reliable predictive value in respect to the efficacy of suramin.

Citing Articles

Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.

Sauvageot C, Weatherbee J, Kesari S, Winters S, Barnes J, DellaGatta J Neuro Oncol. 2008; 11(2):109-21.

PMID: 18682579 PMC: 2718982. DOI: 10.1215/15228517-2008-060.


Multi-agent cytostatic treatment of 'low-grade' gliomas.

Linskey M Curr Oncol Rep. 2000; 2(5):454-62.

PMID: 11122878 DOI: 10.1007/s11912-000-0066-0.


Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status.

Bernsen H, Rijken P, Peters J, BAKKER J, Boerman R, Wesseling P J Neurooncol. 2000; 44(2):129-36.

PMID: 10619496 DOI: 10.1023/a:1006363215260.


Heregulins and the ErbB-2/3/4 receptors in gliomas.

Westphal M, Meima L, Szonyi E, Lofgren J, Meissner H, Hamel W J Neurooncol. 1998; 35(3):335-46.

PMID: 9440030 DOI: 10.1023/a:1005837122181.


Platelet-derived growth factor in human brain tumors.

Kirsch M, Wilson J, Black P J Neurooncol. 1998; 35(3):289-301.

PMID: 9440026 DOI: 10.1023/a:1005872718547.

References
1.
Nister M, Hammacher A, Mellstrom K, Siegbahn A, Ronnstrand L, Westermark B . A glioma-derived PDGF A chain homodimer has different functional activities from a PDGF AB heterodimer purified from human platelets. Cell. 1988; 52(6):791-9. DOI: 10.1016/0092-8674(88)90421-7. View

2.
Hannink M, Donoghue D . Autocrine stimulation by the v-sis gene product requires a ligand-receptor interaction at the cell surface. J Cell Biol. 1988; 107(1):287-98. PMC: 2115171. DOI: 10.1083/jcb.107.1.287. View

3.
Hermansson M, Nister M, Betsholtz C, Heldin C, Westermark B, Funa K . Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. Proc Natl Acad Sci U S A. 1988; 85(20):7748-52. PMC: 282270. DOI: 10.1073/pnas.85.20.7748. View

4.
Richardson W, Pringle N, Mosley M, Westermark B, Dubois-Dalcq M . A role for platelet-derived growth factor in normal gliogenesis in the central nervous system. Cell. 1988; 53(2):309-19. DOI: 10.1016/0092-8674(88)90392-3. View

5.
Sachinidis A, Locher R, Vetter W, Tatje D, Hoppe J . Different effects of platelet-derived growth factor isoforms on rat vascular smooth muscle cells. J Biol Chem. 1990; 265(18):10238-43. View